Piper Sandler Reiterates Overweight Rating on Structure Therapeutics (GPCR)

Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $93.00 price target on Structure Therapeutics (NASDAQ: GPCR).

The analyst commented, "TERN (not covered) unveiled topline data for its 28-day Ph1 study of TERN-601 (oral GLP-1), where patients achieved placebo- adjusted weight loss of up to 4.9%. Accordingly, we point out while this efficacy is comparable to GSBR-1290's placebo-adjusted weight loss of 4.9% on Day 28, GSBR-1290 achieved a more favorable GI tolerability profile across vomiting (50% vs 44-66.7% TERN-601) and constipation (16.7-33.3% vs 10-55.6% TERN-601) in a similar patient population. Considering GPCR is significantly ahead with 36-week Ph2b topline data expected in 4Q25, we also note GPCR is advancing its comprehensive oral small molecule portfolio across multiple MoAs (amylin, GIP-R, apelin, GCG-R). In particular, GPCR's amylin DC is set to be nominated in 4Q24, where we highlight this MoA has been clinically validated by ZEAL's (not covered) petrelintide/NVO's (not covered) amycretin and represents another key value driving opportunity for the name."

For an analyst ratings summary and ratings history on Structure Therapeutics click here. For more ratings news on Structure Therapeutics click here.

Shares of Structure Therapeutics closed at $35.21 yesterday.

You May Also Be Interested In

• Structure Therapeutics (GPCR) PT Lowered to $70 at H.C. Wainwright
• TechCreate Group faces NYSE American delisting proceedings
• Circle board member resigns after nearly 13 years of service